What are the current recommended treatment regimens for drug‑susceptible and multidrug‑resistant tuberculosis?

Current Tuberculosis Treatment Guidelines

Drug-Susceptible Tuberculosis

For newly diagnosed drug-susceptible pulmonary TB, use a 4-month regimen containing rifapentine or the standard 6-month regimen with isoniazid, rifampin, pyrazinamide, and ethambutol. 1

Preferred Regimen Options

Standard 6-Month Regimen (Most Established):

• Intensive phase (8 weeks): Isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) given daily (7 days/week for 56 doses or 5 days/week for 40 doses) 2
• Continuation phase (18 weeks): INH and RIF given daily (7 days/week for 126 doses or 5 days/week for 90 doses) 2
• Total duration: 182-130 doses depending on frequency 2

Novel 4-Month Regimen (Recent Update):

• All-oral regimen for eligible adults and children with pulmonary TB 1
• Represents a significant advancement in shortening treatment duration while maintaining efficacy 1

Special Considerations for Drug-Susceptible TB

Cavitary disease with positive cultures at 2 months:

• Extend continuation phase to 7 months (31 weeks total treatment) 2

Pyridoxine supplementation (25-50 mg daily) is mandatory for:

• Pregnant/breastfeeding women 2
• HIV-positive patients 2
• Patients with diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age 2
• Increase to 100 mg daily if peripheral neuropathy develops 2

Avoid twice-weekly regimens in:

• HIV-infected patients 2
• Smear-positive or cavitary disease 2
• These regimens have inferior outcomes and higher risk of treatment failure and acquired resistance 2

---

Multidrug-Resistant/Rifampin-Resistant Tuberculosis (MDR/RR-TB)

For MDR/RR-TB, the 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid 600mg, moxifloxacin) is now the preferred first-line treatment over longer regimens. 2

MDR/RR-TB Regimen Hierarchy (2022 WHO Update)

First Choice - 6-Month BPaLM/BPaL Regimen:

• Composition: Bedaquiline + pretomanid + linezolid (600 mg) + moxifloxacin (BPaLM) 2
• Duration: 6 months (26 weeks); extend to 9 months if cultures remain positive between months 4-6 2
• Indications: MDR/RR-TB including extensive pulmonary disease, most extrapulmonary TB, and HIV-positive patients 2
• Superior efficacy compared to both 9-month and 18-month traditional regimens 3

BPaL variant (without moxifloxacin):

• Used for pre-extensively drug-resistant TB (fluoroquinolone-resistant) 2
• Can be extended to 9 months total if needed 2

Second Choice - 9-Month All-Oral Regimen:

• Use when 6-month regimen cannot be implemented 2
• Requires documented fluoroquinolone susceptibility 2
• Not suitable for extensive pulmonary TB or pre-extensively drug-resistant cases 2

Third Choice - Longer 18-Month Individualized Regimen:

• Reserved for extensively drug-resistant TB 2
• When shorter regimens contraindicated due to intolerance, drug-drug interactions, or previous treatment failure 2
• CNS TB, miliary TB, and osteoarticular TB 2

Contraindications and Precautions for 6-Month BPaLM

Absolute contraindications:

• Age <14 years 2
• Pregnancy or breastfeeding 2
• Extensively drug-resistant TB (use 18-month regimen instead) 2
• Prior exposure to regimen drugs for ≥30 days without documented susceptibility 2

Use with close monitoring (but not contraindicated):

• Cardiac disease or QTc-prolonging medications 2
• BMI <17 2
• Hemoglobin <7 g/dL or platelets <75,000/mm³ (prefer alternative regimens) 2
• Pre-existing grade III-IV peripheral neuropathy (prefer linezolid-sparing alternatives) 2

---

Essential Treatment Support Components

Case management interventions should be integrated with all TB treatment regimens to improve outcomes beyond medication alone 2:

• Directly observed therapy (DOT): Standard practice for observing medication ingestion 2
• Patient education on disease, treatment expectations, adverse effects, and infection control 2
• Field/home visits and patient reminder systems 2
• Incentives and enablers to support adherence 2
• Integration with primary care, specialty services, and mental health when appropriate 2

Common Pitfalls to Avoid

For drug-susceptible TB:

• Do not use intermittent (twice or thrice weekly) dosing in HIV-positive patients or those with cavitary disease—missed doses become equivalent to once-weekly therapy, which is inferior 2
• Do not forget pyridoxine supplementation in at-risk populations to prevent peripheral neuropathy 2

For MDR/RR-TB:

• Do not use 9-month regimens without confirming fluoroquinolone susceptibility 2
• Do not use 6-month BPaLM in children under 14 or pregnant women 2
• Monitor closely for bedaquiline resistance emergence, particularly in 6-month regimens 3
• Ensure proper cardiac monitoring when using QTc-prolonging agents 2

---

Key Advances in TB Treatment Landscape

The 2022-2025 guideline updates represent a paradigm shift toward shorter, all-oral, more tolerable regimens 2, 1. Treatment success rates for MDR-TB have improved from 50% (2012) to 60% (2019), with the new 6-month regimens showing superior efficacy 2, 3. These advances establish a more patient-centered, equitable model for TB management globally 2.